Document is current
Any future updates will be listed below
-
Authors
Livingston, Nicholas R. https://orcid.org/0000-0002-6582-2545
Calsolaro, Valeria
Hinz, Rainer https://orcid.org/0000-0002-7808-9207
Nowell, Joseph
Raza, Sanara
Gentleman, Steve
Tyacke, Robin J.
Myers, Jim
Venkataraman, Ashwin V.
Perneczky, Robert
Gunn, Roger N.
Rabiner, Eugenii A.
Parker, Christine A.
Murphy, Philip S.
Wren, Paul B.
Nutt, David J. https://orcid.org/0000-0002-1286-1401
Matthews, Paul M. https://orcid.org/0000-0002-1619-8328
Edison, Paul https://orcid.org/0000-0002-6551-2002
-
Funding
Funding for this research was provided by:
GlaxoSmithKline
- License Information
-
More Information
Article History
Received: 25 June 2021
Revised: 10 December 2021
Accepted: 23 December 2021
First Online: 7 February 2022
Competing interests
: PE is a consultant to Roche, Pfizer and Novo Nordisk. He has received speaker fees from Novo Nordisk, Pfizer, Nordea, Piramal Life Science. He has received educational and research grants from GE Healthcare, Novo Nordisk, Piramal Life Science/Life Molecular Imaging, Avid Radiopharmaceuticals and Eli Lilly. He is an external consultant to Novo Nordisk and a member of their Scientific Advisory Board. PMM acknowledges consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or speakers’ honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera.
